MedPath

A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)

Phase 1
Terminated
Conditions
Atopic Dermatitis
Interventions
Device: Wrist Actigraphy Device
Device: Sleep Headband
Registration Number
NCT04262791
Lead Sponsor
AbbVie
Brief Summary

Sleep disturbance is very common in patients with atopic dermatitis (AD) and is a major factor leading to impaired quality of life. Nocturnal scratching is one of the factors causing sleep disturbance in AD patients. This study aims to develop and validate a digital algorithm for accurately and reliably detecting and quantifying nocturnal scratch behaviors related to AD using wrist actigraphy data.

Wrist actigraphy is an investigational device being developed to detect and quantify scratching behaviors in patients with AD. This study will be conducted in 2 sequential stages: In Stage 1, an algorithm will be developed and in Stage 2 the algorithm developed will be validated. Adult healthy volunteers or participants with AD will be enrolled. Approximately 14 healthy volunteers, 14 AD patients with low disease activity and 28 AD patients with high disease activity will be enrolled in the study in 5 sites across the United States.

No drug will be administered as a part of this study.

Participants enrolled in this study may experience discomfort or inconvenience related to the study procedures. Participants will be enrolled and monitored overnight for two consecutive nights at an inpatient setting at a hospital or clinic. The impact of nocturnal scratching on sleep parameters will be assessed by videography, actigraphy, sleep headband and completing questionnaires.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • Volunteers in general good health with no diagnosis of AD or any other dermatologic disorder that interferes with study assessments.

  • For subjects with AD:

  • Chronic AD with onset of symptoms at least 1 year prior to Day 1 and participant meets American Academy of Dermatology (AAD) criteria.

  • Participant meets all of the following disease activity criteria:

    • For AD subjects with high disease activity (AD-High):

      • Pruritus over the last 7 days (numerical rating scale 7-Day version [NRS-7]) >= 4 at the Screening and Day 1 visits.

      • At least one of the following:

        • Eczema Area and Severity Index (EASI) score > 7 at the Screening and Day 1 visits; OR
        • Validated Investigator Global Assessment for AD (vIGA-AD) score >= 3 at the Screening and Day 1 visits;
    • For AD subjects with low disease activity (AD-Low):

      • Pruritus over the last 7 days (NRS-7) >= 2 at the Screening and Day 1 visits.

      • Does not meet AD-High criteria as described.

      • Satisfy at least one of the following:

        • EASI score >= 3 at the Screening and Day 1 visits OR
        • vIGA-AD score >= 1 at the Screening and Day 1 visits.
Read More
Exclusion Criteria
  • Significant eczema on wrists where devices will be worn that, in the opinion of the participant or investigator would likely lead to non-compliance.
  • Interference (e.g., hairstyle) with the ability of Dreem 2 headband to collect sensor data.
  • Unstable medical disorder or other condition that in the investigator's opinion may interfere with study procedures or study objectives.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Healthy VolunteersSleep HeadbandHealthy participants will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2.
Healthy VolunteersWrist Actigraphy DeviceHealthy participants will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2.
Participants With Atopic Dermatitis (AD)Wrist Actigraphy DeviceParticipants with AD will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2. Participants will also be monitored at home via wrist actigraphy, sleep headband when available in the outpatient setting for 7 consecutive nights.
Participants With Atopic Dermatitis (AD)Sleep HeadbandParticipants with AD will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2. Participants will also be monitored at home via wrist actigraphy, sleep headband when available in the outpatient setting for 7 consecutive nights.
Primary Outcome Measures
NameTimeMethod
Total Scratch Duration Per NightUp to 10 Days

Total scratch duration per night (seconds/night) is measured by actigraphy and videography.

Secondary Outcome Measures
NameTimeMethod
Comparison of Actigraphy-Based Scratches to Videography-Based ScratchesUp to 10 Days

Actigraphy-based scratches, as determined by the final algorithm determined in Stage 1, will be compared to videography-based scratches over epoch in which scratch is scored by either actigraphy or videography (and ignoring epochs in which no scratch is scored by either method) over the sleep period.

Scratch DurationUp to 10 Days

Scratch duration is defined as percentage of total rest/sleep time as measured by actigraphy and videography

Number of Scratching EventsUp to 10 Days

Number of scratching events are measured by actigraphy and videography

Scratch RateUp to 10 Days

Scratch rate is measured by actigraphy.

Trial Locations

Locations (3)

PPD Clinical Research Unit /ID# 217010

🇺🇸

Orlando, Florida, United States

Acpru /Id# 217345

🇺🇸

Grayslake, Illinois, United States

Univ Rochester Med Ctr /ID# 217490

🇺🇸

Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath